St. Jude Medical seesaws on FDA warning letter
Wall Street investors send shares of St. Jude Medical up yesterday and down today after the company reveals a warning letter from the FDA over its Sylmar, Calif., Durata defibrillator lead plant.

A warning letter from the FDA to St. Jude Medical [1] (NYSE:STJ [2]) sent the St. Paul, Minn.-based medical device company's stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.